Chapter 18 Changes in the Endocannabinoid System May Give Insight into new and Effective Treatments for Cancer
- 30 July 2009
- book chapter
- review article
- Published by Elsevier BV in Vitamins & Hormones
- Vol. 81, 469-485
- https://doi.org/10.1016/s0083-6729(09)81018-2
Abstract
No abstract availableKeywords
This publication has 67 references indexed in Scilit:
- The endocannabinoid anandamide inhibits cholangiocarcinoma growth via activation of the noncanonical Wnt signaling pathwayAmerican Journal of Physiology-Gastrointestinal and Liver Physiology, 2008
- Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity?Neuropharmacology, 2008
- Inhibition of Cancer Cell Invasion by Cannabinoids via Increased Expression of Tissue Inhibitor of Matrix Metalloproteinases-1JNCI Journal of the National Cancer Institute, 2008
- Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinomaCancer Gene Therapy, 2007
- The orphan receptor GPR55 is a novel cannabinoid receptorBritish Journal of Pharmacology, 2007
- Anandamide inhibits adhesion and migration of breast cancer cellsExperimental Cell Research, 2006
- Anandamide transport: A critical reviewLife Sciences, 2005
- Endocannabinoid metabolism in human glioblastomas and meningiomas compared to human non‐tumour brain tissueJournal of Neurochemistry, 2005
- R(+)-Methanandamide Induces Cyclooxygenase-2 Expression in Human Neuroglioma Cells via a Non-cannabinoid Receptor-Mediated MechanismBiochemical and Biophysical Research Communications, 2001
- Matrix metalloproteinases: molecular aspects of their roles in tumour invasion and metastasisEuropean Journal of Cancer, 2000